Analyst Confidence and Upcoming Events Fuel Optimism for Bayer Shares

Barclays maintains €48 price target on Bayer, citing upside potential ahead of Pharma Media Day. Shares rise as legal overhang clears and earnings outlook stabilizes.

A fresh vote of confidence from Barclays is providing momentum for Bayer's stock ahead of a key company event. The British investment bank has reaffirmed its 'Overweight' rating on the diversified life sciences group, with analyst Charles Pitman-King maintaining a price target of €48.00. This endorsement arrives as investors anticipate deeper insights into the company's pharmaceutical research pipeline tomorrow.

Upward Trajectory and Operational Signals

Market participants responded positively to the analysis on Tuesday, driving Bayer's share price up by 2.34 percent to €39.88. This advance continues a recent upward trend. In his assessment, Pitman-King highlighted significant upside potential, pointing specifically to encouraging operational signals emerging from the pharmaceuticals division.

The fundamental outlook for Bayer appears to be stabilizing. Average analyst forecasts for the ongoing 2026 fiscal year project earnings per share of €4.35. This figure represents a marked improvement over the loss-making quarter at the end of 2025.

A Pivotal Spring Calendar

The company's operational schedule is coming into sharp focus, with several imminent events where management is expected to validate market expectations and provide restructuring details.

• Pharma Media Day, centered on research strategy, is scheduled for April 1, 2026.
• The Annual General Meeting will be held on April 24, 2026.
• First-quarter results for 2026 are due on May 12, 2026.

Tomorrow's presentations at the Pharma Media Day are anticipated to deliver the next concrete catalyst for near-term share price performance.

Legal Clarity as a Cornerstone

A critical factor for the balance sheet remains the execution of the multi-billion euro glyphosate settlement. The provisional judicial approval granted in March has provided much-needed certainty for future planning. The resolution of this longstanding legal overhang is considered a fundamental pillar for the company's financial reassessment.